These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19960185)

  • 21. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
    Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
    J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel advances in the treatment of osteoporosis.
    Chan CK; Mason A; Cooper C; Dennison E
    Br Med Bull; 2016 Sep; 119(1):129-42. PubMed ID: 27558130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lou S; Lv H; Yin P; Li Z; Tang P; Wang Y
    Osteoporos Int; 2019 Jan; 30(1):59-70. PubMed ID: 30539271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoporosis management among chronic glucocorticoid users: a systematic review.
    Albaum JM; Youn S; Levesque LE; Gershon AS; Cadarette SM
    J Popul Ther Clin Pharmacol; 2014; 21(3):e486-504. PubMed ID: 25527817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the guideline of the American College of Physicians on the treatment of osteoporosis.
    Kanis JA; Cooper C; Rizzoli R; Reginster JY
    Osteoporos Int; 2018 Jul; 29(7):1505-1510. PubMed ID: 29869039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
    Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
    Ringe JD; Schacht E
    Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Pathophysiology and Treatment of Osteoporosis.
    Drake MT; Clarke BL; Lewiecki EM
    Clin Ther; 2015 Aug; 37(8):1837-50. PubMed ID: 26163201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Recent progress and problem of treatment with active vitamin D].
    Fukumoto S
    Clin Calcium; 2014 Jan; 24(1):53-8. PubMed ID: 24369280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
    Leder BZ
    Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
    Wagner D; Amrein K; Dimai HP; Kniepeiss D; Tscheliessnigg KH; Kornprat P; Dobnig H; Pieber T; Fahrleitner-Pammer A
    Transplantation; 2012 Feb; 93(3):331-6. PubMed ID: 22217531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
    Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
    Chen L; Wang G; Zheng F; Zhao H; Li H
    Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures.
    Liu Z; Li CW; Mao YF; Liu K; Liang BC; Wu LG; Shi XL
    Orthop Surg; 2019 Jun; 11(3):380-385. PubMed ID: 31058448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS; Chang AB
    Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.